Symptoms and signs of primary melanoma: Important indicators of Breslow depth

Cancer

Volumn 98, Issue 2, 2003, Pages 344-348

  Negin, Benjamin P ^a   Riedel, Elyn ^b   Oliveria, Susan A ^b   Berwick, Marianne ^b   Coit, Daniel G ^b   Brady, Mary S ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Age; Breslow depth; Cutaneous; Gender; Melanoma; Presentation; Signs; Symptoms

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLEEDING; CANCER CENTER; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PAIN; CANCER PATIENT; CANCER SIZE; CLINICAL FEATURE; COLOR; CONTROLLED STUDY; CUTANEOUS MELANOMA; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; SKIN CARCINOMA; SKIN DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MEDICAL HISTORY TAKING; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUESTIONNAIRES; SKIN NEOPLASMS;

EID: 0037669556     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11513     Document Type: Article

References (18)

1. Bishop JA. Melanoma. Hosp Med. 2000;61:103-107.
2. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer. 1998;82:1197-1207.
3. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Johansson H, Ringborg U. Trends in mortality from malignant melanoma in Sweden, 1970-1996. Cancer. 2000; 89:348-355.
4. MacKie RM. Incidence, risk factors and prevention of melanoma. Eur J Cancer. 1998;(34 Suppl 3):S3-S6.
5. van der Rhee HJ, van der Spek-Keijser LM, van Westering R, Coebergh JW. Increase in and stabilization of incidence and mortality of primary cutaneous malignant melanoma in Western Netherlands, 1980-95. Br J Dermatol. 1999;140:463-467.
6. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
7. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol. 1996;34:839-847.
8. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484-1491.
9. Goldstein BG, Goldstein AO. Diagnosis and management of malignant melanoma. Am Fam Physician. 2001;63:1359-1368, 1374.
10. Titus-Ernstoff L. An overview of the epidemiology of cutaneous melanoma. Clin Plast Surg. 2000;27:305-316.
11. Finley JW, Gibbs JF, Rodriguez LM, Letourneau R, Driscoll D, Kraybill W. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system. Am Surg. 2000;66:527-531.
12. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.
13. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27:528-531.
14. Busam KJ. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. Am J Clin Pathol. 2001;115:743-746.
15. McCullagh P. Regression models for ordinal data. J R Stat Soc Ser B. 1980;42:109-142.
16. Wick MM, Sober AJ, Fitzpatrick TB, et al. Clinical characteristics of early cutaneous melanoma. Cancer. 1980;45:2684-2686.
17. Blum A, Brand CU, Ellwanger U, et al. Awareness and early detection of cutaneous melanoma: an analysis of factors related to delay in treatment. Br J Dermatol. 1999;141:783-787.
18. Cassileth BR, Lusk EJ, Guerry D, Clark WH Jr., Matozzo I, Frederick BE. "Catalyst" symptoms in malignant melanoma. J Gen Intern Med. 1987;2:1-4.